United Therapeutics Corp
UTHR Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
UTHR Income Statement
UTHR Balance Sheet
UTHR Cash Flow
Recent trades of UTHR by members of U.S. Congress
UTHR Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
UTHR Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
UTHR Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by UTHR's directors and management
Government lobbying spending instances
-
$40,000 Jan 19, 2010 Issue: Pharmacy Defense Homeland Security Science/Technology
-
$50,000 Oct 19, 2009 Issue: Pharmacy Defense Homeland Security Science/Technology
-
$40,000 Jul 20, 2009 Issue: Science/Technology Homeland Security Defense Pharmacy
-
$40,000 Apr 15, 2009 Issue: Science/Technology Pharmacy Defense Homeland Security
-
$40,000 Jan 16, 2009 Issue: Defense Pharmacy Homeland Security Science/Technology
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Synthesis of esuberaprost prodrugs Dec. 10, 2024
-
Patent Title: Crystalline prostacyclin (ip) receptor agonist and uses thereof Sep. 24, 2024
-
Patent Title: Drug delivery device with electrically controlled volume changing means Sep. 24, 2024
-
Patent Title: Automated bioreactor system, system for automatically implementing protocol for decellularizing organ, and waste decontamination system Jul. 02, 2024
-
Patent Title: Controlled release pharmaceutical formulations Jun. 25, 2024
-
Patent Title: Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells Dec. 12, 2023
-
Patent Title: Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Dec. 12, 2023
-
Patent Title: Stable treprostinil prodrugs Nov. 28, 2023
-
Patent Title: Treatment for interstitial lung disease Nov. 28, 2023
-
Patent Title: Prodrugs of treprosiinil Oct. 24, 2023
-
Patent Title: Treatment for interstitial lung disease Aug. 22, 2023
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Aug. 15, 2023
-
Patent Title: Enhanced solubility drug-containing formulations Jun. 13, 2023
-
Patent Title: Treprostinil prodrugs Jun. 13, 2023
-
Patent Title: Treatment of pulmonary arterial hypertension with mesenchymal stem cells Jun. 06, 2023
-
Patent Title: Treprostinil prodrugs Apr. 25, 2023
-
Patent Title: Size-efficient drug-delivery device Feb. 07, 2023
-
Patent Title: Enhancement of msc immunomodulatory properties by treprostinil Feb. 07, 2023
-
Patent Title: Synthesis of esuberaprost prodrugs Jan. 24, 2023
-
Patent Title: Drug delivery device Jan. 03, 2023
-
Patent Title: Aerosol delivery device and method for manufacturing and operating the same Jul. 05, 2022
-
Patent Title: Treprostinil administration by inhalation Jun. 14, 2022
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Apr. 05, 2022
-
Patent Title: Salts of treprostinil Feb. 01, 2022
-
Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Jan. 18, 2022
-
Patent Title: Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Oct. 12, 2021
-
Patent Title: Controlled release pharmaceutical formulations May. 11, 2021
-
Patent Title: Compounds and methods for delivery of prostacyclin analogs Mar. 16, 2021
-
Patent Title: Extracellular vesicles with enhanced potency Mar. 16, 2021
-
Patent Title: Method for purifying antibodies Feb. 02, 2021
-
Patent Title: Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells Nov. 24, 2020
-
Patent Title: Dosage inhaler Oct. 20, 2020
-
Patent Title: Aerosol delivery device and method for manufacturing and operating the same Oct. 13, 2020
-
Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Sep. 15, 2020
-
Patent Title: Automated bioreactor system, system for automatically implementing protocol for decellularizing organ, and waste decontamination system Sep. 01, 2020
-
Patent Title: Treprostinil administration by inhalation Jul. 21, 2020
-
Patent Title: Inhalation formulations of treprostinil Jun. 30, 2020
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Feb. 04, 2020
-
Patent Title: Controlled release pharmaceutical formulations Dec. 03, 2019
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Nov. 19, 2019
-
Patent Title: Treprostinil administration by inhalation Aug. 13, 2019
-
Patent Title: Process to prepare treprostinil, the active ingredient in remodulin® Jun. 18, 2019
-
Patent Title: Synthesis of intermediates for producing prostacyclin derivatives Feb. 05, 2019
-
Patent Title: Solid forms of treprostinil Jan. 01, 2019
-
Patent Title: Osmotic drug delivery system Dec. 18, 2018
-
Patent Title: Process for making beraprost Oct. 09, 2018
-
Patent Title: Treatment of vasculopathy with prostacyclin and mesenchymal stem cells Sep. 25, 2018
-
Patent Title: Synthesis of intermediate for treprostinil production Sep. 18, 2018
-
Patent Title: Inhalation formulations of treprostinil Sep. 18, 2018
-
Patent Title: Treatment of pulmonary arterial hypertension with mesenchymal stem cells Sep. 11, 2018
Government Contracts
Federal grants, loans, and purchases
- $16,032 2024-12-10 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-12-10 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-11-25 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-11-13 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-11-07 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-10-25 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-10-15 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-10-10 00:00:00 Agency: Department of Veterans Affairs
- $88,162 2024-10-08 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-09-25 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-09-24 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-09-24 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-09-12 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-09-11 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-09-06 00:00:00 Agency: Department of Veterans Affairs
- $0 2024-09-04 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-08-28 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-08-21 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-08-16 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-08-07 00:00:00 Agency: Department of Veterans Affairs
- $31,959 2024-08-05 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-08-02 00:00:00 Agency: Department of Veterans Affairs
- $48,095 2024-08-02 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-07-25 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-07-25 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-07-17 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-07-09 00:00:00 Agency: Department of Veterans Affairs
- $31,959 2024-07-03 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-06-27 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-06-14 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-06-12 00:00:00 Agency: Department of Veterans Affairs
- $58,774 2024-06-12 00:00:00 Agency: Department of Veterans Affairs
- $31,959 2024-06-10 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-06-06 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-05-30 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-05-10 00:00:00 Agency: Department of Veterans Affairs
- $264,485 2024-05-09 00:00:00 Agency: Department of Veterans Affairs
- $16,392 2024-05-07 00:00:00 Agency: Department of Veterans Affairs
- $31,959 2024-05-07 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-05-03 00:00:00 Agency: Department of Veterans Affairs
- $132,243 2024-04-23 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-04-19 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-04-05 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-04-04 00:00:00 Agency: Department of Veterans Affairs
- $88,162 2024-04-04 00:00:00 Agency: Department of Veterans Affairs
- $16,032 2024-04-04 00:00:00 Agency: Department of Veterans Affairs
- $85,328 2024-04-01 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-03-20 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-03-12 00:00:00 Agency: Department of Veterans Affairs
- $14,694 2024-03-12 00:00:00 Agency: Department of Veterans Affairs
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of UTHR in WallStreetBets Daily Discussion
UTHR News
Recent insights relating to UTHR
CNBC Recommendations
Recent picks made for UTHR stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in UTHR
UTHR Top Shareholders
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
UTHR Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view UTHR Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More